Terms: = Prostate cancer AND CUX1, ENSG00000160967, P39880, p75, p200, p110, p100, Nbla10317, CUX, COY1, CDP, CASP, 1523 AND Prognosis
5 results:
1. LEDGF/p75-mediated chemoresistance of mixed-lineage leukemia involves cell survival pathways and super enhancer activators.
Canella A; Van Belle S; Brouns T; Nigita G; Carlon MS; Christ F; Debyser Z
Cancer Gene Ther; 2022 Feb; 29(2):133-140. PubMed ID: 33795806
[TBL] [Abstract] [Full Text] [Related]
2. Positive node burden rather than the number of removed nodes impacts survival in patients with node-positive prostate cancer.
Guo XX; Guo RQ; Hou HM; Wang X; Wang JY; Liu M
Int J Clin Oncol; 2020 Dec; 25(12):2115-2121. PubMed ID: 32748296
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic value of tissue and circulating levels of IMP3 in prostate cancer.
Szarvas T; Tschirdewahn S; Niedworok C; Kramer G; Sevcenco S; Reis H; Shariat SF; Rübben H; vom Dorp F
Int J Cancer; 2014 Oct; 135(7):1596-604. PubMed ID: 24615121
[TBL] [Abstract] [Full Text] [Related]
4. The inhibition of p85αPI3KSer83 phosphorylation prevents cell proliferation and invasion in prostate cancer cells.
Feola A; Cimini A; Migliucci F; Iorio R; Zuchegna C; Rothenberger R; Cito L; Porcellini A; Unteregger G; Tombolini V; Giordano A; Di Domenico M
J Cell Biochem; 2013 Sep; 114(9):2114-9. PubMed ID: 23553770
[TBL] [Abstract] [Full Text] [Related]
5. RelB enhances prostate cancer growth: implications for the role of the nuclear factor-kappaB alternative pathway in tumorigenicity.
Xu Y; Josson S; Fang F; Oberley TD; St Clair DK; Wan XS; Sun Y; Bakthavatchalu V; Muthuswamy A; St Clair WH
Cancer Res; 2009 Apr; 69(8):3267-71. PubMed ID: 19351823
[TBL] [Abstract] [Full Text] [Related]
